DAVID GRANOVSKY

Posts Tagged ‘STUDY’

ROUND UP DAMAGES EMBRYONIC, PLACENTAL AND UMBILICAL CORD CELLS

In ALL ARTICLES, OFF THE BEATEN PATH, STEM CELLS IN THE NEWS on June 20, 2014 at 12:23 pm

roundup-the-ultimate-killing-machine

ROUND UP DAMAGES EMBRYONIC, PLACENTAL AND UMBILICAL CORD CELLS

Chemicals in Round Up are targeting both our reproductive abilities and our regenerative/healing abilities.  But we’ve know this for a long time.  What’s special about this article is that it is in Scientific American, “The leading source and authority for science, technology information and policy for a general audience”

From the article:
“Monsanto scientists argue that cells in Seralini’s study were exposed to unnaturally high levels of the chemicals…Seralini’s team, however, did study multiple concentrations of Roundup. These ranged from the typical agricultural or lawn dose down to concentrations 100,000 times more dilute than the products sold on shelves. The researchers saw cell damage at all concentrations.”

So while Monsanto scientists say the study used unnaturally high amounts, this is false,  The study included samples 100,000 TIMES MORE DILUTE than average exposures AND IT STILL CAUSED CELL DAMAGE.

Cell damage to

  • EMBRYONIC CELLS
  • PLACENTAL CELLS
  • UMBILICAL CORD CELLS

The corner stone to both our reproductive and regenerative capabilities.  Think you’re safe? Roundup Weedkiller Found In 75% of Air and Rain Samples, Gov. Study Finds

You idiots.  You’ve killed us all.

statue_planet

http://www.scientificamerican.com/article/weed-whacking-herbicide-p/

PIONEERING??? Heart Study

In ALL ARTICLES, CATCH UP!, STEM CELLS IN THE NEWS on February 20, 2013 at 9:27 am

This makes me crazy.  Thousands, maybe tens of thousands treated to date successfully with studies going back to 2002 and they call this brand new study pioneering?  Consider the triple blind study protocol used:

  • 1/3 RECEIVE NOTHING AT ALL
  • 1/3 RECEIVE A PLACEBO
  • 1/3 RECEIVE STEM CELLS

The odds are not in his favor to even get the treatment.  It’s time to catch up to the rest of the world. – DG

DeBary man takes part in pioneering stem cell study

Dr. David Henderson, left, talks to his patient Robert Anderson, 64, of DeBary recently at Florida Hospital Memorial Medical Center in Daytona Beach. Anderson is participating in a clinical research trial that uses a patient’s own stem cells to regenerate cardiovascular tissue. He was the first patient to enroll in the clinical study that started in December at Cardiology Research Associates of Florida Hospital Memorial Medical Center.

News-Journal/STEVEN NOTARAS

By
STAFF WRITER
Published: Monday, February 18, 2013 at 5:30 a.m.
Last Modified: Sunday, February 17, 2013 at 5:41 p.m.

DAYTONA BEACH — At 44, Robert Anderson’s career as a chemical engineer was cut short due to pain in his chest and jaw.

A few years earlier doctors had performed bypass surgery on Anderson to repair the deteriorating muscle around his heart. Like 850,000 Americans, Anderson suffers from angina, which causes chest discomfort due to coronary heart disease.

But the surgery was a temporary fix for Anderson, whose diabetes worsened his heart condition. As the pain in his jaw and chest increased when he walked, the DeBary resident was forced into early retirement.

For the past 20 years, Anderson’s life has been limited by his heart condition, which has only worsened.

With no surgical options left, Anderson is hoping his participation in a clinical research trial that uses a patient’s own stem cells to regenerate cardiovascular tissue will improve his quality of life. Some patients taking part in the study also were injected with a placebo…

WHAT IF GERTRUDE STEIN AND MR. ED HAD A STEM CELL BABY…

In VICTORIES & SUCCESS STORIES on January 23, 2012 at 4:01 am

Some articles are not only fascinating but they lend themselves so easily to have a little bit of fun with.  With apologies to both Gertrude Stein and Mr. Ed (and a richly deserved apology to the good Dr. Goodrich):

WHAT IF GERTRUDE STEIN AND MR. ED

LITERALLY HAD A STEM CELL BABY…

The following study researched the effectiveness of bone marrow stem cells taken from 2 different sites on horses – the hip bone (iliac crest) and the sternum.

In the end, there was very little difference between the results of stem cells taken from the two sites.  This information has extremely significant therapeutic relevance as doctors can now focus on other criteria for site selection; ease of extraction, quantity of  cells, proportion of cell types, etc.  Further, this study reinforces the idioms:

“A ROSE IS A ROSE IS A ROSE”

“A STEM CELL IS A STEM CELL IS A STEM CELL”

“A HORSE IS A HORSE, OF COURSE, OF COURSE”

“A HORSE STEM CELL IS A HORSE STEM CELL, OF COURSE, OF COURSE”

Apologies to Will Shakespeare for being odd man out at the dance.  Now to worry; you are gone but not forgotten.

“A stem cell by any other derivation site would smell just as sweet.”

(Four more equine stem cell articles below)

………………

Bone Marrow-Derived Stem Cell Sources Compared (AAEP 2011)

Stem cell source site has been debated among researchers in recent years as stem cells have been gaining popularity in equine medicine. A research group at Colorado State University recently compared the use of bone marrow-derived mesenchymal stem cells from two sites on the horse’s body to determine which might be most effective for treating specific soft tissue injuries. Laurie Goodrich, DVM, PhD, Dipl. ACVS, presented results at the 2011 American Association of Equine Practitioners Convention, held Nov. 18-22 in San Antonio, Texas.

According to Goodrich, stem cells are particularly useful for treating tissues such as joints and tendons-these tissues lack regenerative capability due to a deficiency in local stem cell response. Stem cells have been derived from adipose tissue (fat) and bone-marrow. However, for tendon healing, bone marrow-derived cells yield better matrix and collagen production, she noted.

The research team compared bone marrow-derived mesenchymal stem cells (BM-MSCs) from the two most common extraction sites in the horse: the sternum (breastbone) and the ilium (hip). For BM-MSC therapy to be effective, Goodrich said two aspects are crucial: using large numbers of cells (roughly 5-10 million cells/centimeter in tendon and 5-10 million cells/joint) and implanting the cells early during the critical period between the inflammatory and fibroblastic phases of healing.

Goodrich discussed previously noted advantages and disadvantages for each site:

For the sternum:

  • Advantages
    • The bone marrow aspirate flows better into the syringe;
    • The amount of aspirate is not influenced by age of the horse; and
    • Cells are easier to collect.
  • Disadvantages:
    • The site is close to vital structures (heart, lungs); and
    • The collector must crouch under the horse.

For the ilium:

  • Advantages
    • Practitioner doesn’t have to crouch while obtaining cells; and
    • There’s no risk of jabbing the heart or lungs.
  • Disadvantages
    • It’s more difficult to get adequate cell volume;
    • The sample size is age-dependent; and
    • Ilial samples often result in unsuccessful culture.

Explore the power of the human-horse connection as you travel the emotional journey that veterinarians at Rood and Riddle Equine Hospital and owners embark on when a beloved horse becomes ill in Equine ER

Researchers and clinicians had also noticed that the cells from sternal samples appeared different from those in ilial bone marrow samples.

Goodrich’s study sought to provide clinicians with better information to guide selection site and on whether the health of the MSCs varied between separate samples or (fractions) of bone marrow drawn from a site at one time. Goodrich and her co-authors examined two sequential 5 mL samples from both sternal and ilial bone marrow aspirates of seven horses (they “plated” cells from the sample/grew them in culture, referred to as a “passage”). They found that:

  • The first fractions of both samples yielded the highest cell counts;
  • The cells of the first fraction were no healthier than those of the second;
  • The health of the sternal and ilial samples was the same;
  • By the second and third culture passages, cell morphologies were similar between the two sites; and
  • Aspirates greater than 5-10 mL produced insignificant increases to the nucleated cell count.
  • Goodrich noted the following limitations to the study:
  • A relatively small number of horses was used;
  • There was some variability in age and gender of the horses; and
  • They didn’t calculate the cell-doubling times, although the measurement of cell numbers at each passage was more relevant.

Goodrich’s team concluded that bone marrow aspiration site should depend on clinician preference, since the cells of one site do not appear to be superior to the other.

via The Horse | Bone Marrow-Derived Stem Cell Sources Compared (AAEP 2011).

OTHER EQUINE STEM CELL ARTICLES:

Lions and puppys and horseys, oh my! « The Stem Cell Blog

repairstemcell.wordpress.com/…/lions-and-puppys-and-horseys-oh-m…

Mar 7, 2009 – http://repairstemcell.wordpress.com/2009/02/27/horse-racing-horse-racing-samantha-miss-has-stem-cell-treatment/

ANIMALS + STEM CELLS « The Stem Cell Blog

repairstemcell.wordpress.com/animals-stem-cells/

http://repairstemcell.wordpress.com/2009/02/27/equine-clinic-is-full-service-care-for-hoofed-friends-thecaliforniancom-the-salinas-californian/

GERON GIVES UP on EMBRYONIC STEM CELLS! « The Stem Cell …

repairstemcell.wordpress.com/…/geron-gives-up-on-embryonic-stem-…

Nov 14, 2011 – If Embryonic treatments were a horse race, Geron would be the strongest ….. repairstemcell.wordpress.com/2009/02/18/jewish-law-articles-the-

KCBS – Stem Cell Research on Horses Holds Promise for Human …

repairstemcell.wordpress.com/…/kcbs-stem-cell-research-on-horses-h…

May 20, 2009 – http://repairstemcell.wordpress.com/2009/02/27/equine-clinic-is-full-service-care-for-hoofed-friends-thecaliforniancom-the-salinas-californian/

INTESTINAL STEM CELLS RESPOND TO FOOD BY SUPERSIZING THE GUT

In STEM CELLS IN THE NEWS on October 27, 2011 at 6:24 pm

Request more treatment info.

INTESTINAL STEM CELLS RESPOND TO FOOD BY SUPERSIZING THE GUT

SO now we know that stem cells change your body all the time to deal with changes in your environment and what you eat.  Is it getting clearer? – David

Intestinal stem cells respond to food by supersizing the gut

BERKELEY —

A new study from University of California, Berkeley, researchers demonstrates that adult stem cells can reshape our organs in response to changes in the body and the environment, a finding that could have implications for diabetes and obesity…

Intestinal stem cells respond to food by supersizing the gut.

DIABETES CLINICAL TRIALS

  • FIRST USE OF CORD BLOOD TO ALTER COURSE OF TYPE 1 DIABETES, June 25, 2007 – (I’ll bet nobody heard of this one!)transfusion of stored, autologous (i.e. the person’s own), umbilical cord blood into a group of children newly diagnosed with type 1 diabetes appears to have reduced their disease severity, possibly re-setting the immune system and slowing the destruction of their insulin-producing cells, according to a report presented today at the American Diabetes Association’s 67th Annual Scientific Sessions. –http://parentsguidecordblood.org/content/media/m_pdf/ADA_T1D_PR-06-25-07.pdf(The ADA in 2007 knew stem cells can treat Diabetes type 1 in children!)
  • Diabetes type 1 stem cell clinical trial – Enrollment 11/2003-4/2008, follow-up until December 2008 – https://repairstemcell.wordpress.com/2009/09/14/type-1-diabetes-stem-cells-clinical-trial/
  • Why no diabetes clinical trial s in the US when mice were cured of diabetes type 1 in the 1990’s? –  Weissman, a professor of pathology and developmental biology at Stanford University, states: “Stem cells are rare, self-renewing, and can regenerate body tissues.” He repeatedly expressed frustration that while many of his discoveries seemed to hold remarkable potential for life-saving treatments, commercial or regulatory hurdles have prevented his scientific research from benefiting human beings. One example is, his mid-’90s research on type I diabetes, in which he demonstrated the ability to fully cure type I diabetes in mice using stem cells. Even though the experiments avoided political controversy by using adult/repair stem cells, which do not come from embryos, Weissman ran into a road block when pharmaceutical companies refused to sponsor clinical trials. The therapy went nowhere. “The pharmaceutical companies had put profit over principle, preferring to keep diabetes sufferers dependent on costly insulin than to cure them once and for all.” – https://repairstemcell.wordpress.com/2009/09/13/research-from-90s-cures-type-1-diabetes/

If you or a loved one is interested in receiving FREE information on currently available stem cell treatments for DIABETES or PERIPHERAL ARTERY DISEASE, please contact me at dsgrano@gmail.com or for other options, go to: CONTACT ME

FAKE AND FRAUDULENT SCIENCE

In DISEASE INFO on October 27, 2011 at 2:32 am

FAKE AND FRAUDULENT SCIENCE

  • Scientific empirical data is subject to misinformation and corruption as much as what some refer to as the “soccer mom hysteria.”
    For example:  Dr Thorsen’s data on the correlation between MMR vaccines and Autism is corrupt and dependent on elements outside the study both ignored and cherry picked around:

    “Thorsen was a leading member of a Danish research group that wrote several key studies supporting CDC’s claims that the MMR vaccine and mercury-laden vaccines were safe for children. Thorsen’s 2003 Danish study reported a 20-fold increase in autism in Denmark after that country banned mercury based preservatives in its vaccines. His study concluded that mercury could therefore not be the culprit behind the autism epidemic.

    His study has long been criticized as fraudulent since it failed to disclose that the increase was an artifact of new mandates requiring, for the first time, that autism cases be reported on the national registry. This new law and the opening of a clinic dedicated to autism treatment in Copenhagen accounted for the sudden rise in reported cases rather than, as Thorsen seemed to suggest, the removal of mercury from vaccines. Despite this obvious chicanery, CDC has long touted the study as the principal proof that mercury-laced vaccines are safe for infants and young children. Mainstream media, particularly the New York Times, has relied on this study as the basis for its public assurances that it is safe to inject young children with mercury — a potent neurotoxin — at concentrations hundreds of times over the U.S. safety limits.

    Thorsen, who was a psychiatrist and not a research scientist or toxicologist, parlayed that study into a long-term relationship with CDC. He built a research empire called the North Atlantic Epidemiology Alliances (NANEA) that advertised its close association with the CDC autism team, a relationship that had the agency paying Thorsen and his research staff millions of dollars to churn out research papers, many of them assuring the public on the issue of vaccine safety.

    The discovery of Thorsen’s fraud came as the result of an investigation by Aarhus University and CDC which discovered that Thorsen had falsified documents and, in violation of university rules, was accepting salaries from both the Danish university and Emory University in Atlanta — near CDC headquarters — where he led research efforts to defend the role of vaccines in causing autism and other brain disorders. Thorsen’s center has received $14.6 million from CDC since 2002.

    Thorsen’s partner Kreesten Madsen recently came under fierce criticism after damning e-mails surfaced showing Madsen in cahoots with CDC officials intent on fraudulently cherry picking facts to prove vaccine safety.

    Leading independent scientists have accused CDC of concealing the clear link between the dramatic increases in mercury-laced child vaccinations beginning in 1989 and the epidemic of autism, neurological disorders and other illnesses affecting every generation of American children since. Questions about Thorsens’s scientific integrity may finally force CDC to rethink the vaccine protocols since most of the other key pro vaccine studies cited by CDC rely on the findings of Thorsen’s research group. These include oft referenced research articles published by the Journal of the American Medical Association, the American Journal of Preventive Medicine, the American Academy of Pediatrics, the New England Journal of Medicine and others. The validity of all these studies is now in question.”

    via https://repairstemcell.wordpress.com/2010/03/15/cdc-vaccine-cover-up-mercury-actually-does-cause-autism/

mercury toxic element,Who Discovered Mercury,mercury element,toxic,tannoy f4 custom,poisoning symptoms,interesting facts about mercury,facts on the planet,outboard motors,how many moons does,how far is from the sun, insurance complaints,lithgow mercury,outboard motor parts,passenger vehicles e bay motors,manhattan mercury,who discovered the planet,pottstown mercury newspaper,mercury gemini mind games,mercury engine oil,what color is mercury,pictures of mercury,mercury grand  marquie clubs,mercury symbol,san jose mercury newspaper

 

  • PFIZER, CELEBREX, BEXTRA + VIOXX CLINICAL TRIAL RESULTS WERE FAKE- FRAUD
    February 18, 2010 at 1:55 pm “It’s being called the largest research fraud in medical history. Dr. Scott Reuben, a former member of Pfizer’s speakers’ bureau, has agreed to plead guilty to faking dozens of research studies that were published in medical journals. Now being reported across the mainstream media is the fact that Dr. Reuben accepted a $75,000 grant from Pfizer to study Celebrex in 2005. His research, which was published in a medical journal, has since been quoted by hundreds of other doctors and researchers as “proof” that Celebrex helped reduce pain during post-surgical recovery. There’s only one problem with all this: No patients were ever enrolled in the study!” https://repairstemcell.wordpress.com/2010/02/18/pfizer-celebrex-bextra-vioxx-clinical-trial-results-were-fake-fraud/


    repairstemcell.wordpress.com

    ‎”It’s being called the largest research fraud in medical history. Dr. Scott Reu…

 

  • and need I mention the Embyonic hoax perpetrated on the US populace for a decade?

    The pure and impartial and just eye of the scientist is just as susceptible to partiality as any other if not more so because they think thy can get away with it.

    The Placebo Defecthttp://naturalnews.com/030209_placebo_medical_fraud.html

    “This is the conclusion from researchers at the University of California who published their findings in the October issue of the Annals of Internal Medicine. They reviewed 167 placebo-controlled trials published in peer-reviewed medical journals in 2008 and 2009 and found that 92 percent of those trials never even described the ingredients of their placebo pills.”

    Empirical science is not a hat you take off when it is convenient. Everything has an effect and if test tubes are not sterile and compounds are contaminated and trials are screwed up then they can not be considered valid. 92%. Nuff said.

https://i2.wp.com/no92.com/assets/images/autogen/a_nO92_logo.gif

DIABETES and STEM CELL TREATMENTS AVAILABLE

In ALL ARTICLES on October 24, 2011 at 9:15 am

Anyone interested in treatment info with one of the best stem cell diabetes doctors in the world can contact me or fill out this form: 
TREATMENT INFORMATION REQUEST – PATIENT QUESTIONNAIRE

——————————-

Can stem cells cure Diabetes – type 1?

In VICTORIES & SUCCESS STORIES on August 31, 2009 at 12:00 pm

Can stem cells cure Diabetes – type 1? See the results of this one year study of adult stem cell treatment of Diabetes type – 1. C-peptide levels, insulin levels, insulin dosage requirements and HA1c levels.

asc_04

asc_05

asc_06

asc_07

Can stem cells cure Diabetes – type 2?

In VICTORIES & SUCCESS STORIES on August 31, 2009 at 12:12 pm

Can stem cells cure Diabetes – type 2? See the results of this one year study of adult stem cell treatment of Diabetes type – 2.  C-peptide levels, insulin levels, insulin dosage requirements and HA1c levels.

asc_10

asc_11

asc_12

asc_13

DIABETES CLINICAL TRIALS

  • FIRST USE OF CORD BLOOD TO ALTER COURSE OF TYPE 1 DIABETES, June 25, 2007 – (I’ll bet nobody heard of this one!)transfusion of stored, autologous (i.e. the person’s own), umbilical cord blood into a group of children newly diagnosed with type 1 diabetes appears to have reduced their disease severity, possibly re-setting the immune system and slowing the destruction of their insulin-producing cells, according to a report presented today at the American Diabetes Association’s 67th Annual Scientific Sessions. –http://parentsguidecordblood.org/content/media/m_pdf/ADA_T1D_PR-06-25-07.pdf(The ADA in 2007 knew stem cells can treat Diabetes type 1 in children!)
  • Diabetes type 1 stem cell clinical trial – Enrollment 11/2003-4/2008, follow-up until December 2008 – https://repairstemcell.wordpress.com/2009/09/14/type-1-diabetes-stem-cells-clinical-trial/

Images from above are from these articles:

  • Why no diabetes clinical trial s in the US when mice were cured of diabetes type 1 in the 1990’s? –  Weissman, a professor of pathology and developmental biology at Stanford University, states: “Stem cells are rare, self-renewing, and can regenerate body tissues.” He repeatedly expressed frustration that while many of his discoveries seemed to hold remarkable potential for life-saving treatments, commercial or regulatory hurdles have prevented his scientific research from benefiting human beings. One example is, his mid-’90s research on type I diabetes, in which he demonstrated the ability to fully cure type I diabetes in mice using stem cells. Even though the experiments avoided political controversy by using adult/repair stem cells, which do not come from embryos, Weissman ran into a road block when pharmaceutical companies refused to sponsor clinical trials. The therapy went nowhere. “The pharmaceutical companies had put profit over principle, preferring to keep diabetes sufferers dependent on costly insulin than to cure them once and for all.” – https://repairstemcell.wordpress.com/2009/09/13/research-from-90s-cures-type-1-diabetes/

If you or a loved one is interested in receiving FREE information on currently available stem cell treatments for DIABETES, please contact me at dsgrano@gmail.com or for other options, go to: CONTACT ME

Embryonic Stem Cell Studies Front Page News as Better Adult Studies Ignored

In ALL ARTICLES on September 26, 2011 at 8:02 am
Wednesday, September 21, 2011, 2:35 PM
Wesley J. Smith

Good grief.  Here we go again.

The SF Chronicle has a front page story about the fourth human subject to receive an embryonic stem cell-derived injection of cells.  From the story:

A Bay Area patient who recently suffered a serious spinal cord injury and is now paralyzed from the waist down joined the world’s first-ever embryonic stem cell study in humans last week, when Stanford doctors injected 2 million cells designed to replace damaged neurons in the patient’s spine. The patient, who is not being identified, is the fourth person to be enrolled in the clinical trial being run by Menlo Park’s Geron Corp. and the first person in California. The patient, whose participation in the trial was revealed Tuesday, received the stem cell injection Saturday at Santa Clara Valley Medical Center and is now at the rehabilitation center there.

And no matter what happens, the test is an advance!

Regardless of the outcome, the study is a major step forward in stem cell research, researchers say, and scientists from all over the field will be watching the results carefully.

Here’s the thing:  This isn’t news.  The patient is merely the fourth person enrolled in an uncompleted safety study of six (I think that’s the number).  The California angle is just an excuse for a press release and a fawning front page story pushing ESCR.

At the same time, there have been years of successful and peer reviewed adult stem cell studies involving patients paralyzed by spinal cord injury–in which patients have had feeling restored–which went virtually unreported.  If it isn’t embryonic, to the MSM, it often just isn’t worth mentioning.

Think I exaggerate?  Let’s take a look at one from 2009.  Paralyzed patients who had no use of their legs, were able to ambulate after a combination of surgery and adult stem cell therapy.  From the Wayne State University press release:

The injuries in the study patients were 18 months to 15 years old. The patients, ages 19 to 37, had no use of their legs before the treatment. One paraplegic treated almost three years after the injury now ambulates with two crutches and knee braces. Ten other patients ambulate with physical assistance and walkers (with and without braces). One 31-year-old male tetriplegic patient uses a walker without the help of knee braces or physical assistance. When the stem cell transplant and scar removal process was combined with an advanced form of rehabilitative training that employs brain-initiated weight-bearing movement, 13 patients improved in the standard measures used to assess functional independence and walking capabilities. 

Did you miss the front page stories about this very encouraging early study?  Yea, me too. (Here’s a link to the peer reviewed published report.)

I somehow also missed the headlines about restored feeling for subjects with total loss of sensation published in Spinal Cord:

Thirty-nine consecutive patients with diagnosed complete cervical and thoracic SCI for at least 2 years and with no cortical response in the SSEP study of the lower limbs were included in the trial. The trial patients underwent peripheral blood stem cell mobilization and collection. The stem cell concentrate was cryopreserved and reinfused through arteriography into the donor patient. The patients were followed up for 2.5 years and submitted to SSEP studies to evaluate the improvement in SSEPs after undifferentiated cell infusion. Twenty-six (66.7%) patients showed recovery of somatosensory evoked response to peripheral stimuli after 2.5 years of follow-up. 

This general ignoring of adult successes and boosting less impressive embryonic studies has been going on a long time, as I reported in “The Great Stem Cell Coverup,” published in the Weekly Standard back in 2006.

So, in summary: The media often over report embryonic stem cell stories and badly under report better results when they happen with adult stem cells.  Just another example of media often not reporting the actual story, but the story they want to report.

Via

GERON’S EMBRYONIC “WASTE OF TIME” CONTINUES…

In ALL ARTICLES on September 21, 2011 at 9:51 pm

Here’s an 867 word article I’d like to not waste your time with.

https://i1.wp.com/www.epiphanymarketing.com/blog/wp-content/uploads/2010/03/waste-of-time-283x300.jpg

The premise is:  “The study is not meant to determine whether the stem cells can cure or even improve the patients’ condition, but to find out if the treatment itself is safe. Researchers will be monitoring patients over the following months and years to look for side effects, including possible benign tumor growth if the stem cells start to replicate, or adverse immune reactions.”

So let’s not waste your time, I’ll give you the results right now:

EMBRYONIC STEM CELL = ESC

  • SOURCE/DERIVED FROM•comes from embryos
  • PURPOSE IN BODY•split for 7 weeks until you have a fetus the size of a thumbnail
  • OBSTACLES+SIDE EFFECTS•they create cysts and tumors, rejection requires immunosuppressive drugs for the ill patient, they carry the genetic anomalies of the donor, etc
  • TREATMENT HISTORY•can currently treat zero diseases, probably need to cure cancer first to use them

Read it if you want but that’s really “all she wrote.”  Then again, this will allow billions to be pumped into embryonic research for treatments over “the following months and years” despite this fact…

SCREW THE EMBRYOS, THEY’RE IRRELEVANT!

———————————————

———————————————

Paralyzed patient in major Geron stem cell study

Erin Allday, Chronicle Staff Writer, Wednesday, September 21, 2011

A Bay Area patient who recently suffered a serious spinal cord injury and is now paralyzed from the waist down joined the world’s first-ever embryonic stem cell study in humans last week, when Stanford doctors injected 2 million cells designed to replace damaged neurons in the patient’s spine.

The patient, who is not being identified, is the fourth person to be enrolled in the clinical trial being run by Menlo Park’s Geron Corp. and the first person in California. The patient, whose participation in the trial was revealed Tuesday, received the stem cell injection Saturday at Santa Clara Valley Medical Center and is now at the rehabilitation center there.

The study is not meant to determine whether the stem cells can cure or even improve the patients’ condition, but to find out if the treatment itself is safe. Researchers will be monitoring patients over the following months and years to look for side effects, including possible benign tumor growth if the stem cells start to replicate, or adverse immune reactions…

Read more

STEM CELLS FOR MS

In STEM CELLS IN THE NEWS on September 17, 2011 at 9:42 am

MORE CONFIRMATION IT WORKS!

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Suppl 2):72-6.

[Transplantation of mesenchymal

stem cells in multiple sclerosis].

Abstract

To assess safety and tolerability of treatment with autologic multipotent mesenchymal stem cells (MSC) in multiple sclerosis (MS), we have obtained autologic red bone marrow-derived MSC from 8 patients. Proliferation, immunophenotype and caryotype of MSC, their sterility, the absence of hemopoetic cells, chromosomal aberrations and signs of aging were controlled during the cell growth. The inverse injection of MSC in patient’s blood was conducted in accordance to the elaborated protocol in a short intravenous infusion in dose 2.0 x 10(6)/kg of body mass once in 30 days.

  • The duration of treatment was from 4 to 8 months.
  • The efficacy of treatment was assessed after 4, 8 and 12 months.
  • All patients tolerated repeated intravenous infusions of autologic MSC well with no significant side-effects as in the early as well in the remote periods of treatment.
  • The distinct positive effect was seen in some cases 2 months after the beginning of treatment.
  • The improvement of 0.5 point on EDSS was seen in 5/8 patients after 4 months.
  • After 12 months, the improvement of 0.5-1 point on EDSS was seen in 6/8, stabilization in 1/8, progression in 1/8.
  • These results revealed the safety of the elaborated protocol of treatment and the moderate clinical efficacy of treatment in non-curable patients or those with poor response to treatment that suggested continuing the study and enrollment of new patients.

Reuters Health Update

In ALL ARTICLES on April 22, 2011 at 3:38 pm

New studies point to clot risk of Bayer’s Yasmin
April 21, 2011 06:34 PM ET
FRANKFURT (Reuters) – New evidence emerged on Friday that women taking Bayer’s best-selling contraceptive Yasmin may run a higher risk of dangerous blood clots than those using older birth-control pills. | Full Article
No evidence coffee ups risk of high blood pressure
April 22, 2011 07:52 AM ET
NEW YORK (Reuters Health) – Despite earlier concerns, downing lots of coffee doesn’t seem to increase the risk of high blood pressure, according to a new report — but the evidence isn’t conclusive. | Full Article
Many kids with diabetes have other immune diseases
April 21, 2011 05:29 PM ET
NEW YORK (Reuters Health) – A third of children with type 1 diabetes have signs of other immune system disorders when they get diagnosed with diabetes, according to a new study. | Full Article
%d bloggers like this: